Clinical Trial Update: Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

This document outlines a Phase 1/2 clinical trial evaluating a combination of homoharringtonine, a BCL-2 inhibitor, rituximab, and prednisone for relapsed or re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• BCL-2 inhibitor
• Homoharringtonine (homoharringtonine)
• PREDNISONE (Prednisone)
• Rituximab (rituximab)

Snippet

Sponsor: First Affiliated Hospital of Zhejiang University | Conditions: Diffuse Large B-Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING